Cantor Fitzgerald Brokers Lift Earnings Estimates for ATOS

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities researchers at Cantor Fitzgerald increased their FY2024 earnings per share estimates for shares of Atossa Therapeutics in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($0.20) per share for the year, up from their previous forecast of ($0.22). The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.21) per share.

ATOS has been the subject of a number of other reports. HC Wainwright lifted their target price on shares of Atossa Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday. Finally, Ascendiant Capital Markets boosted their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a report on Wednesday, September 11th.

Atossa Therapeutics Stock Performance

Shares of ATOS stock opened at $1.28 on Monday. Atossa Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $2.31. The firm has a market capitalization of $161.03 million, a price-to-earnings ratio of -5.82 and a beta of 1.23. The stock’s 50-day simple moving average is $1.44 and its 200-day simple moving average is $1.37.

Institutional Investors Weigh In On Atossa Therapeutics

A number of large investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock valued at $4,278,000 after acquiring an additional 44,762 shares during the period. Barclays PLC increased its stake in shares of Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after acquiring an additional 123,683 shares during the period. XTX Topco Ltd raised its holdings in shares of Atossa Therapeutics by 101.2% during the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after purchasing an additional 24,951 shares during the last quarter. State Street Corp lifted its position in Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after purchasing an additional 69,180 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in Atossa Therapeutics in the third quarter valued at $75,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.